FINSUM + Magnifi: Healthcare Will be a Headliner Even After the Pandemic

April 23, 2021

Healthcare has been one of the dominant stories of the pandemic, but its stock prices haven't matched the pace of the overall market. Healthcare stocks have lagged the S&P 500 earnings by 5% YTD. However, the biggest reason for this is the pandemic has shifted priorities and healthcare relies on the overall economy (making up about 18% of GDP) to pick up before it can fully bounce back. Additionally, the Biden Administration has yet to appoint a Food and Drug Commissioner which will be crucial in the upcoming years. However, valuations and earnings reports have been positive: UnitedHealth trades at 21x this year's forecast and Pfizer about 12x, well within normalcy. Healthcare will be in a good position as more speculative stocks settle down.

(Boston)


FINSUM + Magnifi: Economic growth is the key here. As the economy bounces back healthcare will eat its same piece of the pie, and there will be great value in healthcare funds.

Other news today: Bank of America Warns Investors of Bond Market Correction and Tech Sector Health Looks Strong on IBM Earnings


New call-to-action

Magnifi is changing the way we shop for investments, with the world’s first semantic search engine for finance that helps users discover, compare and buy investment products such as ETFs, mutual funds and stocks. As of April 2021, 300,000+ users with $500+ Billion in Assets Under Influence, have used Magnifi over 1,500,000 times. Try it for yourself today.

 

This blog is sponsored by Magnifi. The information and data are as of the publish date unless otherwise noted and subject to change. This material is provided for informational purposes only and should not be construed as individualized investment advice or an offer or solicitation to buy or sell securities tailored to your needs. This information covers investment and market activity, industry or sector trends, or other broad-based economic or market conditions and should not be construed as investment research or advice. Investors are urged to consult with their financial advisors before buying or selling any securities. Although certain information has been obtained from sources believed to be reliable, we do not guarantee its accuracy, completeness or fairness. Past performance is no guarantee of future results. This content may not be reproduced or distributed to any person in whole or in part without the prior written consent of Magnifi. [As a technology company, Magnifi provides access to tools and will be compensated for providing such access. Magnifi does not provide brokerage or custody services.]

 

Magnifi in Action: Discover "Top Healthcare Funds"

Click on any fund in the chart below to dig deeper.

Related Posts

FINSUM + Magnifi: Pharma Still a Value Play Despite Being a Key Industry in the Pandemic

(March 2021)

Most pharmaceutical companies kicked it into high gear to develop the Covid-19...

FINSUM + Magnifi: Why Healthcare ETFs are About to Win

(March 2021)

The multinational biopharmaceutical company Amgen has agreed to terms to acquire...

FINSUM + Magnifi: This New Treatment Spells a Turnaround for Biotech Behemoth

(March 2021)

Vertex Pharmaceuticals was a shining star amongst the already bright biotech...

FINSUM + Magnifi: Potential Trouble in the High Yield Market

(October 2020)

 

The high yield bond market is sending some very odd signals. Over the month of...